TruScreen, the cervical cancer test developer which is listed on the NZX Alternative Market, has been publicly censured by the New Zealand Markets Disciplinary Tribunal for having just one New Zealand resident director for 18 business days, falling short of the requirement for at least two, after former director Tim Preston withdrew his nomination on the eve of the company's annual meeting in September.
The stock market's disciplinary tribunal said TruScreen had only one director who was ordinarily resident in New Zealand following its September 21 annual meeting. Still, it noted Preston's withdrawal from re-election was not known until the AGM and the company took immediate steps to find a suitable replacement and promptly appointed new director Ron Jones.
"The corporate governance provisions of the rules are important to the integrity of the market," the Tribunal said in a statement posted on the NZX. The policy "is to ensure issuers have directors who are available to both New Zealand resident shareholders and the New Zealand regulatory authorities."
Preston, who has a capital markets background, joined the TruScreen board in 2014 ahead of its listing that year and had unanimous board support for re-election in the notice of meeting to shareholders on September 5.
However, he withdrew his nomination and the resolution wasn't put to shareholders, saying that the company's governance needed greater diversity and a wider skill set to help roll out its products into international markets.